Last reviewed · How we verify

NCT06277414

a Prediction of Post-Endoscopic Retrograde Cholangiopancreatography Complication

Status unknown Last updated 26 February 2024
What this trial tests

trial testing collection of laboratory test results, imaging results and symptoms in Endoscopic Retrograde Cholangiopancreatography in 2,000 participants. Status unknown.

Timeline
1 January 2018
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorThe First Affiliated Hospital of University of South China
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment2,000
Start date1 January 2018
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First Affiliated Hospital of University of South China

Who can join

Adults 18 to 90, any sex, with Endoscopic Retrograde Cholangiopancreatography. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To develop effective preoperative and postoperative prediction models for postoperative complications of ERCP

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Endoscopic Retrograde Cholangiopancreatography

Currently open trials in the same condition.

Other The First Affiliated Hospital of University of South China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06277414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing